Literature DB >> 23553424

Letter to the editor: pharmacokinetics of non-intravenous formulations of fentanyl.

Donald R Taylor, Allen W Burton, Nashat Y Gabrail, Didier Mayeur, Philippe Poulain, Alain Serrie, Luis M Torres.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23553424     DOI： 10.1007/s40262-013-0059-4

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  3 in total

1.  Fentanyl Pectin Nasal Spray reduces breakthrough cancer pain intensity compared with placebo in people taking at least 60 mg daily oral morphine or equivalent.

Authors:  Carol P Curtiss
Journal:  Evid Based Nurs       Date:  2011-05-10

2.  A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.

Authors:  Russell K Portenoy; Allen W Burton; Nashat Gabrail; Donald Taylor
Journal:  Pain       Date:  2010-08-25       Impact factor: 6.961

Review 3.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.